Annals of Clinical and Translational Neurology · 2019 · 46 citations · 52 references
MedicineNeurosciencePharmacologyEpilepsyMolecular NeuroscienceNeuropharmacologyAntiepileptic PharmacologyAntiepileptic PharmacotherapyElectroencephalography In EpilepsyTuberous Sclerosis ComplexGene DeletionMammalian Target Of Rapamycin SignalingMtor Pathway EpilepsiesMtorc1 SignalingRodent EpilepsyTsc1 GeneTuberous Sclerosis Complex SignalingTuberous Sclerosis-associated Epilepsy
OBJECTIVE: An epilepsy mouse model for Tuberous Sclerosis Complex (TSC) was developed and validated to investigate the mechanisms underlying epileptogenesis. Furthermore, the possible antiepileptogenic properties of commonly used antiepileptic drugs (AEDs) and new compounds were assessed. METHODS: Tsc1 deletion was induced in CAMK2A-expressing neurons of adult mice. The antiepileptogenic properties of commonly used AEDs and inhibitors of the mTOR pathways were assessed by EEG recordings and by molecular read outs. RESULTS: Mice developed epilepsy in a narrow time window (10 ± 2 days) upon Tsc1 gene deletion. Seizure frequency but not duration increased over time. Seizures were lethal within 18 days, were unpredictable, and did not correlate to seizure onset, length or frequency, reminiscent of sudden unexpected death in epilepsy (SUDEP). Tsc1 gene deletion resulted in a strong activation of the mTORC1 pathway, and both epileptogenesis and lethality could be entirely prevented by RHEB1 gene deletion or rapamycin treatment. However, other inhibitors of the mTOR pathway such as AZD8055 and PF4708671 were ineffective. Except for ketogenic diet, none of commonly used AEDs showed an effect on mTORC1 activity. Vigabatrin and ketogenic diet treatment were able to significantly delay seizure onset. In contrast, survival was shortened by lamotrigine. INTERPRETATION: This novel Tsc1 mouse model is highly suitable to assess the efficacy of antiepileptic and -epileptogenic drugs to treat mTORC1-dependent epilepsy. Additionally, it allows us to study the mechanisms underlying mTORC1-mediated epileptogenesis and SUDEP. We found that early treatment with vigabatrin was not able to prevent epilepsy, but significantly delayed seizure onset.
52
Simon A. Hawley, Matt Davison, Angela Woods et al. · Journal of Biological Chemistry · 1996 · 1.3K citations · Full text
Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 795 citations · Full text
Medicine, Oncology, Pharmacology +13
Jacqueline A. French, John A. Lawson, Hiroko Ikeda et al. · The Lancet · 2016 · 747 citations · Full text
The natural history of epilepsy in tuberous sclerosis complex
Catherine J. Chu, Philippe Major, Susana Camposano et al. · Epilepsia · 2009 · 632 citations · Full text
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex
Ling-Hui Zeng, Lin Xu, David H. Gutmann et al. · Annals of Neurology · 2008 · 632 citations · Full text
Medicine, Neurology, Neuroscience +17